Bulletin
Investor Alert

GT Biopharma Inc.

NAS: GTBP

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
GT Biopharma Inc.

After Hours

 --Quotes are delayed by 20 min

Mar 31, 2023, 6:52 p.m.

GTBP
/zigman2/quotes/200365724/composite

$

0.55

Change

-0.0050 -0.91%

Volume

Volume 8

Quotes are delayed by 20 min

/zigman2/quotes/200365724/composite

Previous close

$ 0.46

$ 0.55

Change

+0.09 +18.33%

Day low

Day high

$0.49

$0.57

Open

52 week low

52 week high

$0.44

$3.29

Open

Company Description

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a pati...

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in Brisbane, CA.

Valuation

Price to Book Ratio

4.46

Enterprise Value to EBITDA

0.29

Total Debt to Enterprise Value

0.00

Efficiency

Income Per Employee

-7,251,625.00

Liquidity

Current Ratio

3.14

Quick Ratio

3.14

Cash Ratio

3.12

Profitability

Return on Assets

-306.70

Return on Total Capital

-613.07

Capital Structure

Total Debt to Total Equity

0.14

Total Debt to Total Capital

0.14

Total Debt to Total Assets

0.10

Officers and Executives

Name Age Officer Since Title
Mr. Michael Breen 58 2021 Independent Director
Mr. Manu Ohri 65 2022 Chief Financial Officer
Ms. Kathy Quandt - 2021 Controller
Dr. Rajesh C. Shrotriya 77 2021 Independent Director
Mr. Bruce Jeffrey Wendel 67 2020 Vice Chairman

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
12/22/2020 Steven W. Weldon
47,978   Disposition at $0.4 per share. 19,191
12/21/2020 Steven W. Weldon
35,722   Disposition at $0.34 per share. 12,145
12/21/2020 Steven W. Weldon
50,000   Disposition at $0.33 per share. 16,500
12/21/2020 Steven W. Weldon
50,000   Disposition at $0.3 per share. 15,000
12/18/2020 Steven W. Weldon
50,000   Disposition at $0.3 per share. 15,000
12/17/2020 Steven W. Weldon
50,000   Disposition at $0.31 per share. 15,500
12/17/2020 Steven W. Weldon
50,000   Disposition at $0.3 per share. 15,000
12/16/2020 Steven W. Weldon
50,000   Disposition at $0.3 per share. 15,000
12/15/2020 Steven W. Weldon
50,000   Disposition at $0.32 per share. 16,000
12/15/2020 Steven W. Weldon
50,000   Disposition at $0.3 per share. 15,000
12/15/2020 Steven W. Weldon
50,000   Disposition at $0.3 per share. 15,000
12/14/2020 Steven W. Weldon
46,300   Disposition at $0.29 per share. 13,427
12/14/2020 Steven W. Weldon
50,000   Disposition at $0.29 per share. 14,500
12/14/2020 Steven W. Weldon
50,000   Disposition at $0.28 per share. 14,000
12/11/2020 Steven W. Weldon
50,000   Disposition at $0.26 per share. 13,000
12/11/2020 Steven W. Weldon
50,000   Disposition at $0.25 per share. 12,500
06/02/2020 Anthony J. Cataldo
CEO; Director 		4,234,320   Disposition at $0 per share. 0
05/13/2020 Steven W. Weldon
2,269,708   Disposition at $0 per share. 0
/news/latest/company/us/gtbp

MarketWatch News on GTBP

  1. GT Biopharma started at buy with $21 stock price target at B. Riley

    8:17 a.m. April 13, 2021

    - Tomi Kilgore

  2. MannKind CEO, Exec Bought Stock in December

    6:55 a.m. Dec. 27, 2017

    - Barron's Online

  3. Axonyx acquires controlling interest in OXIS Intl.

    9:54 a.m. Jan. 20, 2004

    - Maggie McNeil

  4. Stocks to watch: Aventis, Catapult Communications and more

    7:26 p.m. Dec. 23, 1999

    - CBS.MarketWatch.com

  5. Oxis shares rise

    6:18 p.m. Dec. 23, 1999

    - CBS.MarketWatch.com

  6. Personal Finance: The year-end 401(k) catch-up game

    1:39 p.m. Dec. 23, 1999

    - Alan Feigenbaum

  7. Oxis shares rise

    1:34 p.m. Dec. 23, 1999

    - CBS.MarketWatch.com

  8. November income, spending rise; durable orders rebound

    12:11 p.m. Dec. 23, 1999

    - CBS.MarketWatch.com

  9. Paul Farrell's commentary: Holidays too hectic? Take a short break

    12:05 p.m. Dec. 23, 1999

    - Dr. Paul B. Farrell

/news/nonmarketwatch/company/us/gtbp

Other News on GTBP

  1. 10-K: GT BIOPHARMA, INC.

    5:03 p.m. March 30, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  2. 10-Q: GT BIOPHARMA, INC.

    5:25 p.m. Oct. 31, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  3. GT Biopharma files for $150M mixed shelf offering

    6:22 p.m. Oct. 13, 2022

    - Seeking Alpha

  4. 10-Q: GT BIOPHARMA, INC.

    9:47 a.m. Aug. 15, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  5. GT Biopharma GAAP EPS of -$0.10 beats by $0.07

    9:48 a.m. Aug. 11, 2022

    - Seeking Alpha

  9. Has Geron (GERN) Outpaced Other Medical Stocks This Year?

    9:40 a.m. June 10, 2022

    - Zacks.com

  10. 10-Q: GT BIOPHARMA, INC.

    9:08 a.m. May 16, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  12. GT Biopharma names Manu Ohri as CFO

    8:44 a.m. Feb. 18, 2022

    - Seeking Alpha

  14. GT Biopharma: Shift In Therapy Strategy Reduces Attractiveness

    2:44 a.m. Nov. 15, 2021

    - Seeking Alpha

  15. CBAT, ADS and NETI among mid-day movers

    1:47 p.m. Nov. 8, 2021

    - Seeking Alpha

  16. GT Biopharma falls 21% after CEO and CFO leave company

    1:42 p.m. Nov. 8, 2021

    - Seeking Alpha

  17. Warning: GTBP is at high risk of performing badly

    5:04 a.m. Nov. 5, 2021

    - Seeking Alpha

  18. Warning: GTBP is at high risk of performing badly

    4:55 a.m. Oct. 27, 2021

    - Seeking Alpha

  20. Warning: GTBP has been downgraded to Very Bearish

    4:29 a.m. Sept. 28, 2021

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

GT Biopharma, Inc.

8000 Marina Boulevard

Suite 100

Brisbane, California 94005

Phone

1 4159194040

Industry

Pharmaceuticals

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2022

View SEC Filings

Revenue

N/A

Net Income

$-58.01M

Employees

8.00

Annual Report for GTBP

/news/pressrelease/company/us/gtbp

Press Releases on GTBP

  21. Loading more headlines...
Link to MarketWatch's Slice.